Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Harvard Bioscience Q3 Revenue Rises 8% to $22.2 Million

None

Harvard Bioscience (HBIO) reported third-quarter 2026 revenue of $22.2 million, up 8% from $20.6 million a year earlier. The company posted a GAAP net loss of $2.6 million, or $0.58 per basic and diluted share, compared with a $1.2 million loss, or $0.28 per share, in the prior-year quarter.

For the first nine months of 2026, revenue was $65.7 million and GAAP net loss was $9.0 million. Harvard Bioscience reaffirmed full-year revenue-growth guidance of 3% to 5%.

  • Third-quarter gross profit was $12.3 million, with gross margin of 55.4%, versus 58.4% a year earlier.
  • Third-quarter adjusted EBITDA was $1.8 million, compared with $2.0 million in the prior-year period.
  • Fourth-quarter revenue guidance is $23.7 million to $25.5 million.
  • Cash and cash equivalents totaled $4.9 million as of September 30, 2026.
  • The company said Project Viking remains on track for completion by the end of the first quarter of 2027.
EARLY ACCESS
Receive HBIO Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$HBIO Hedge Fund Activity

We have seen 8 institutional investors add shares of $HBIO stock to their portfolio, and 19 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles